Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines

PLoS One. 2016 Jun 30;11(6):e0157290. doi: 10.1371/journal.pone.0157290. eCollection 2016.

Abstract

Retinoic acid (RA), the main active vitamin A metabolite, controls multiple biological processes such as cell proliferation and differentiation through genomic programs and kinase cascades activation. Due to these properties, RA has proven anti-cancer capacity. Several breast cancer cells respond to the antiproliferative effects of RA, while others are RA-resistant. However, the overall signaling and transcriptional pathways that are altered in such cells have not been elucidated. Here, in a large-scale analysis of the phosphoproteins and in a genome-wide analysis of the RA-regulated genes, we compared two human breast cancer cell lines, a RA-responsive one, the MCF7 cell line, and a RA-resistant one, the BT474 cell line, which depicts several alterations of the "kinome". Using high-resolution nano-LC-LTQ-Orbitrap mass spectrometry associated to phosphopeptide enrichment, we found that several proteins involved in signaling and in transcription, are differentially phosphorylated before and after RA addition. The paradigm of these proteins is the RA receptor α (RARα), which was phosphorylated in MCF7 cells but not in BT474 cells after RA addition. The panel of the RA-regulated genes was also different. Overall our results indicate that RA resistance might correlate with the deregulation of the phosphoproteome with consequences on gene expression.

MeSH terms

  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Cell Differentiation / drug effects
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Phosphoproteins / metabolism*
  • Phosphorylation / drug effects
  • Proteome / drug effects*
  • Signal Transduction / drug effects
  • Transcriptome / drug effects*
  • Tretinoin / pharmacology*

Substances

  • Phosphoproteins
  • Proteome
  • Tretinoin

Grants and funding

This work was supported by funds from CNRS, INSERM and by funds raised by CRE from the Agence Nationale pour la Recherche (ANR-09-BLAN-0297-01, www.agence-nationale-recherche.fr), the Association pour la recherche sur le Cancer (SL 220110603474 and PJA20141201746, www.fondation-arc.org), the Fondation pour la Recherche Médicale (FRM, DEQ20090515423, www.frm.org), and the Institut National du Cancer (PL09-194, www.e-cancer.fr). It was also supported by ANR-10-LABX-0030-INRT, a French State fund managed by the ANR under the frame programme Investissements d’Avenir labeled ANR-10-IDEX-0002-02. ARC supported the acquisition of the Orbitrap mass spectrometer. The Canceropole Grand Est supported MJ. The Ligue nationale contre le cancer supported MC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.